MoonLake Immunotherapeutics MLTX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's total equity?
- MoonLake Immunotherapeutics (MLTX) reported total equity of $254.02M in Q1 2026.
- How has MoonLake Immunotherapeutics's total equity changed year-over-year?
- MoonLake Immunotherapeutics's total equity decreased by 37.7% year-over-year, from $407.52M to $254.02M.
- What is the long-term trend for MoonLake Immunotherapeutics's total equity?
- Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's total equity has grown at a 161.0% compound annual growth rate (CAGR), from -$2.52M to $304.48M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.